# NCT05012371 (NCT05012371)

> Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus everolimus
- Indication: metastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05012371
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Cabozantinib; Everolimus; Lenvatinib; Questionnaire Administration
- Enrollment: 90
- Primary outcome: Progression-Free Survival (PFS)

## Indexed commentary on NCT05012371 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 YouTube videos
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05012371
